Exosome blood test aims to catch ovarian cancer recurrence earlier
NCT ID NCT07153705
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests a new blood test (OCS) that uses exosome technology to monitor for ovarian cancer recurrence in patients whose CA125 levels were normal before their first treatment. About 32 women with stage I-IV ovarian cancer will provide blood samples after initial surgery and chemotherapy. The goal is to find a more reliable way to detect if the cancer comes back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.